Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Inventors:
Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
Abstract: The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
August 28, 2020
Publication date:
September 22, 2022
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
Martha Alicia DE LA ROSA, John MILLER, Lita S. SUWANDI, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: The invention relates to compounds of Formulae (I) and (II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
July 30, 2020
Publication date:
August 18, 2022
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
John MILLER, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
Inventors:
Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
Abstract: The invention relates to compounds of the Formula: salts thereof, pharmaceutical compositions thereof, combinations thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
August 8, 2019
Publication date:
April 21, 2022
Applicants:
GlaxoSmithKline Intellectual Property (No. 2) Limited, VIIV Healthcare Company
Inventors:
John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lita SUWANDI, B. Narasimhulu NAIDU
Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
Inventors:
Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
Inventors:
Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Peng Li, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm
Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
Inventors:
Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CII2CII3, —CII2?CII2, —CII2CII2CII3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
January 4, 2022
Assignees:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
Inventors:
Carlos Alemparte-Gallardo, Michael Richard Kevin (Dickon) Alley, David Barros-Aguirre, Ilaria Giordano, Vincent Hernandez, Xianfeng Li, Jacob J. Plattner
Abstract: Methods for the preparation of the following compound are disclosed. The compound can be incorporated into pharmaceutical formulations, including tablets and such tablets can be used for treating cholestatic liver diseases.
Abstract: The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
August 28, 2019
Publication date:
October 21, 2021
Applicants:
GlaxosmithKline Intellectual Property (No. 2) Limited, ViiV Healthcare Company
Inventors:
John MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lisa SUWANDI
Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
Abstract: The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases.
Inventors:
Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Gemma Michele Liwicki, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson